header
Image from OpenLibrary

Clinical significance of connexin 32 and connexin 43 expression in acute myeloid leukemia / Aliaa Ibrahim Aly Hassan Seif ; Supervised Ahmed Aly Shams Eldin , Dalia Gameel Ameen , Mohamed Ahmed Fateen

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Aliaa Ibrahim Aly Hassan Seif , 2017Description: 181 P. : charts , facsimiles ; 25cmOther title:
  • الدلاله الاكلينيكية للتعبير عن كونكسين 32 وكونكسين 43 عند مرضي سرطان الدم الميلودي الحاد [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology Summary: Cx32 and Cx43 are Gap junctions consist of arrays of intercellular channels. Cx43 is the major component of hematopoietic tissue, Cx32 was also found to be important in bone marrow stromal cells so they may play a role in leukemogenesis. The aim of this study was to evaluate the expression of Connexin 32 and Connexin 43 expression profiles and to correlate their expression with disease severity and other prognostic markers in Egyptian patients with Acute myeloid leukemia. Real time PCR was used to assess the gene expressions patterns in 60 de novo AML patients in addition to 40 normal controls.The study revealed an increased expression of Connexin 32 along with a statistically significant difference between AML de novo patients in comparison to the control group (median Cx32=18,p=0.009). Also Connexin 43 expression showed lower median fold change along with a statistically significant difference between AML de novo patients in comparison to the control group (median Cx43=0.6,p=0.013). The expression of Connexin 32 and Connexin 43 was lower in AML FAB subtype M3 patients with a significant difference against FAB subtypes (M1,M2) and FAB subtypes with monocytic differetiantion (M4,M5) (median Cx32= 0.48, median Cx43= 0.1 and Cx32p=0.009, Cx43p=0.002) with a slight increase of the level of expression in FAB subtypes with monocytic differentiation (M4,M5) against FAB subtypes (M1,M2 and M3) but with no significant difference (median Cx32= 26.5, median Cx43= 0.7 and Cx32p=0.216, Cx43p=0.403). CD 34 positive AML patients showed a significantly higher level of Cx32 and Cx43 expression against CD34 negative AML patients (Cx32p=0.045, Cx43p=0.007). No statistically significant difference was found in Connexin 32 and Connexin 43 fold change expression in AML patients as regards their outcome after first induction. No statistically significant difference was found between favorable risk patients and those with intermediate/unfavourable risk in Connexin 32 and Connexin 43 fold change expression
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.07.Ph.D.2017.Al.C (Browse shelf(Opens below)) Not for loan 01010110075713000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.07.Ph.D.2017.Al.C (Browse shelf(Opens below)) 75713.CD Not for loan 01020110075713000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology

Cx32 and Cx43 are Gap junctions consist of arrays of intercellular channels. Cx43 is the major component of hematopoietic tissue, Cx32 was also found to be important in bone marrow stromal cells so they may play a role in leukemogenesis. The aim of this study was to evaluate the expression of Connexin 32 and Connexin 43 expression profiles and to correlate their expression with disease severity and other prognostic markers in Egyptian patients with Acute myeloid leukemia. Real time PCR was used to assess the gene expressions patterns in 60 de novo AML patients in addition to 40 normal controls.The study revealed an increased expression of Connexin 32 along with a statistically significant difference between AML de novo patients in comparison to the control group (median Cx32=18,p=0.009). Also Connexin 43 expression showed lower median fold change along with a statistically significant difference between AML de novo patients in comparison to the control group (median Cx43=0.6,p=0.013). The expression of Connexin 32 and Connexin 43 was lower in AML FAB subtype M3 patients with a significant difference against FAB subtypes (M1,M2) and FAB subtypes with monocytic differetiantion (M4,M5) (median Cx32= 0.48, median Cx43= 0.1 and Cx32p=0.009, Cx43p=0.002) with a slight increase of the level of expression in FAB subtypes with monocytic differentiation (M4,M5) against FAB subtypes (M1,M2 and M3) but with no significant difference (median Cx32= 26.5, median Cx43= 0.7 and Cx32p=0.216, Cx43p=0.403). CD 34 positive AML patients showed a significantly higher level of Cx32 and Cx43 expression against CD34 negative AML patients (Cx32p=0.045, Cx43p=0.007). No statistically significant difference was found in Connexin 32 and Connexin 43 fold change expression in AML patients as regards their outcome after first induction. No statistically significant difference was found between favorable risk patients and those with intermediate/unfavourable risk in Connexin 32 and Connexin 43 fold change expression

Issued also as CD

There are no comments on this title.

to post a comment.